Research & Development News
ComCor study: New results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
WHO update on Omicron
On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE that Omicron has several mutations that may have an impact on how it behaves, for example, on how easily it spreads or the severity of illness it causes. Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggressive brain tumor.
International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform
Aspirin is linked with increased risk of heart failure
Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity
More Pharma News ...
Business & Industry
- GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
- Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
- Pfizer and BioNTech receive expanded U.S. FDA emergency use suthorization of COVID-19 vaccine booster to include individuals 18 and older
- GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
- Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19
Research & Development
- Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
- ComCor study: New results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
- WHO update on Omicron
- Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
- International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform
- Aspirin is linked with increased risk of heart failure
- Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity
Conferences & Events
- Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
Regulatory Affairs
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
- FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
- FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
- FDA approves innovative treatment for pediatric patients with congenital athymia